Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-26T05:28:09.028Z Has data issue: false hasContentIssue false
  • English
  • Français

Sacubitril/Valsartan: potential treatment for paediatric heart failure

Published online by Cambridge University Press:  06 July 2018

Bibhuti B. Das Open the ORCID record for Bibhuti B. Das [Opens in a new window] ,
Frank Scholl ,
Breanna Vandale  and
Maryanne Chrisant
Bibhuti B. Das*
Affiliation:
Joe DiMaggio Children’s Hospital Heart Institute, Memorial Health Care, Hollywood, FL, USA
Frank Scholl
Affiliation:
Joe DiMaggio Children’s Hospital Heart Institute, Memorial Health Care, Hollywood, FL, USA
Breanna Vandale
Affiliation:
Joe DiMaggio Children’s Hospital Heart Institute, Memorial Health Care, Hollywood, FL, USA
Maryanne Chrisant
Affiliation:
Joe DiMaggio Children’s Hospital Heart Institute, Memorial Health Care, Hollywood, FL, USA
*
Author for correspondence: B. B. Das, MD, FAAP, FACC, Joe DiMaggio Children’s Hospital Heart Institute, Memorial Health Care, 1150 North 35 Avenue, Hollywood, FL 33021, USA. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.

Keywords

Paediatric heart failureangiotensin receptor blockerneprilysin inhibitor
Type
Review Article
Information
Cardiology in the Young , Volume 28 , Issue 9 , September 2018 , pp. 1077 - 1081
Check for updates
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Cite this article: Das BB, Scholl F, Vandale B, Chrisant M. (2018) Sacubitril/Valsartan: potential treatment for paediatric heart failure. Cardiology in the Young28: 1077–1081. doi: 10.1017/S104795111800080X

References

1. Kirk, R, Dipchand, AI, Rosenthal, DN, et al. The international Society of Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. J Heart Lung Transplant 2014; 33: 888–909.CrossRefGoogle ScholarPubMed
2. Rosenthal, D, Chrisant, M, Edens, E, et al. International Society of Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. J Heart Lung Transpl 2004; 23: 1313–1333.CrossRefGoogle ScholarPubMed
3. Lipshultz, SE, Sleeper, LA, Towbin, JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003; 24: 1647–1655.CrossRefGoogle Scholar
4. Nugent, AW, Daubeney, PE, Chondros, P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003; 348: 1639–1646.CrossRefGoogle ScholarPubMed
5. Andrew, RE, Fenton, MJ, Ridout, DA, Burch, M. New-onset heart failure due to heart muscle disease in childhood: a prospective study in United Kingdom and Ireland. Circulation 2008; 117: 79–84.CrossRefGoogle Scholar
6. Dipchand, AI, Kirk, R, Edwards, LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Pediatric Heart Transplantation Report-2013; focus theme: age. J Heart Lung Transpl 2013; 32: 979–988.CrossRefGoogle ScholarPubMed
7. Rossano, JW, Shaddy, RE. Heart failure in children: etiology and treatment. J Pediatr 2014; 165: 228–233.CrossRefGoogle ScholarPubMed
8. Sipido, KR, Eisner, D. Something old, something new: changing views on the cellular mechanism of heart failure. Cardiovasc Research 2005; 68: 167–174.CrossRefGoogle Scholar
9. Scoote, M, Poole-Wilson, PA, Williams, AJ. The therapeutic potential of new insights into myocardial excitation-contraction coupling. Heart 2003; 89: 371–376.CrossRefGoogle ScholarPubMed
10. Kantor, PF, Lougheed, J, Dancea, A, et al. Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines. Can J Cardiol 2013; 29: 1535–1552.CrossRefGoogle ScholarPubMed
11. Krum, H, Shi, H, Pitt, B, et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy; analysis of the EMPHASIS-HF study. Circ Heart Fail 2013; 6: 711–718.CrossRefGoogle ScholarPubMed
12. Das, BB, Solinger, R. Role of natriuretic peptide family in cardiovascular medicine. Cardiovasc Hematol Agents Med Chem 2009; 7: 29–42.CrossRefGoogle ScholarPubMed
13. Nagaya, N, Satoh, T, Nishikimi, T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2000; 101: 498–503.CrossRefGoogle ScholarPubMed
14. Knecht, M, Pagel, I, Langenickel, T, et al. Increased expression of neural neutral endopeptidase in severe heart failure. Life Sci 2002; 71: 2701–2712.CrossRefGoogle Scholar
15. Braunwald, E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Col Card 2015; 65: 1029–1041.CrossRefGoogle Scholar
16. Goldsmith, S. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep 2004; 1: 45–50.CrossRefGoogle ScholarPubMed
17. Packer, M, Califf, RM, Konstam, MA, et al. Comparison of Omapatrilat versus Enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 2002; 106: 920–926.CrossRefGoogle ScholarPubMed
18. Cohn, JN, Tognoni, G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–1675.CrossRefGoogle ScholarPubMed
19. McMurray, JV, Packer, M, Desai, AD, et al. Angiotensin-Neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004.CrossRefGoogle ScholarPubMed
20. Desai, AS, McMurray, JJV, Milton, P, et al. Effects of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015; 36: 1990–1997.CrossRefGoogle ScholarPubMed
21. Patel, MD, Mohan, J, Schneider, C, et al. Pediatric and adult dilated cardiomyopathy represent distinct pathological entities. JCI Insight 2017; July 20: 2: 94382.CrossRefGoogle Scholar
22. Miyamoto, SD, Stauffer, BL, Nakuno, S, et al. Beta-adrenergic adaptation in pediatric idiopathic dilated cardiomyopathy. Eur Heart J 2012; 35: 1–9.Google ScholarPubMed
23. Nakano, SJ, Sucharov, J, van Dusen, R, et al. Cardiac adenylyl cyclase and phosphodiesterase expression profiles vary by age, disease, and chronic phosphodiesterase inhibitor treatment. J card fail 2017; 23: 72–80.CrossRefGoogle ScholarPubMed
24. Shaddy, RE, Boucek, MM, Hsu, DT, et al. Carvedilol for children and adolescent with heart failure: a randomized controlled trial. J Am Med Assoc 2007; 298: 1171–1179.CrossRefGoogle ScholarPubMed
25. Almond, CSD, Thiagrajan, RR, Piercey, GE, et al. Waiting list mortality among children listed for heart transplantation in children in the United States. Circulation 2009; 5: 717–727.CrossRefGoogle Scholar
26. International Society of Heart and Lung Registry Data. J Heart Lung Transplant 2017; 36: 1037–1079.CrossRefGoogle Scholar
27. Packer, M, McMurray, JJV, Desai, AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015; 131: 54–61.CrossRefGoogle ScholarPubMed
28. Solomon, SD, Rizkala, AR, Gong, J, et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail 2017; 7: 471–482.CrossRefGoogle Scholar
29. Ruilope, LM, Dukat, A, Bohm, M, et al. Blood-pressure reduction with LCZ696, a novel dual acting inhibitor of the angiotensin II receptor and neprilysin: a randomized, double-blinded, placebo-controlled, active comparator study. Lancet 2010; 375: 1255–1266.CrossRefGoogle ScholarPubMed
30. Ponikowski, P, Voors, A, Anker, S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 2016; 74: 891–975.CrossRefGoogle ScholarPubMed
31. Yancy, C, Jessup, M, Bozkurt, B, et al. 2017 ACC/AHA/HSFA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guidelines for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017; 23: 776–803.CrossRefGoogle Scholar
32. Shaddy, R, Canter, C, Halnon, N, et al. Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left heart ventricle systolic dysfunction. Am Heart J 2017; 193: 23–34.CrossRefGoogle ScholarPubMed